Clinical trial
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With…
NCT00300950 · GlobeImmune, Industry · Completed
Key facts
| NCT number | NCT00300950 |
|---|---|
| Title | Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer |
| Official title | A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients… |
| Lead sponsor | GlobeImmune, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreas Cancer |
| Intervention type | Biological, Drug |
| Interventions | GI-4000, Gemcitabine |
| Enrollment | 176 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2015 |
| Completion | Feb 1, 2015 |
| First posted | Mar 10, 2006 |
| Last update posted | Apr 6, 2015 |
| Countries | India, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: